Effects of metformin on retinoblastoma growth in vitro and in vivo

Brodowska,Katarzyna; Theodoropoulou,Sofia; Meyer Zu Hörste,Melissa; Paschalis,Eleftherios  I.; Takeuchi,Kimio; Scott,Gordon; Ramsey,David  J.; Kiernan,Elizabeth; Hoang,Mien; Cichy,Joanna; Miller,Joan  W.; Gragoudas,Evangelos   S.; Vavvas,Demetrios  G.

doi:10.3892/ijo.2014.2650

Effects of metformin on retinoblastoma growth in vitro and in vivo

Authors:
- Katarzyna Brodowska
- Sofia Theodoropoulou
- Melissa Meyer Zu Hörste
- Eleftherios I. Paschalis
- Kimio Takeuchi
- Gordon Scott
- David J. Ramsey
- Elizabeth Kiernan
- Mien Hoang
- Joanna Cichy
- Joan W. Miller
- Evangelos S. Gragoudas
- Demetrios G. Vavvas
View Affiliations

Affiliations: Retina Service, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA, Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
Published online on: September 11, 2014 https://doi.org/10.3892/ijo.2014.2650
Pages: 2311-2324

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies suggest that the anti‑diabetic drug metformin may reduce the risk of cancer and have anti‑proliferative effects for some but not all cancers. In this study, we examined the effects of metformin on human retinoblastoma cell proliferation in vitro and in vivo. Two different human retinoblastoma cell lines (Y79, WERI) were treated with metformin in vitro and xenografts of Y79 cells were established in nu/nu immune‑deficient mice and used to assess the effects of pharmacological levels of metformin in vivo. Metformin inhibited proliferation of the retinoblastoma cells in vitro. Similar to other studies, high concentrations of metformin (mM) blocked the cell cycle in G0‑G1, indicated by a strong decrease of G1 cyclins, especially cyclin D, cyclin‑dependent kinases (4 and 6), and flow cytometry assessment of the cell cycle. This was associated with activation of AMPK, inhibition of the mTOR pathways and autophagy marker LC3B. However, metformin failed to suppress growth of xenografted tumors of Y79 human retinoblastoma cells in nu/nu mice, even when treated with a maximally tolerated dose level achieved in human patients. In conclusion, suprapharmacological levels (mM) of metformin, well above those tolerated in vivo, inhibited the proliferation of retinoblastoma cells in vitro. However, physiological levels of metformin, such as seen in the clinical setting, did not affect the growth of retinoblastoma cells in vitro or in vivo. This suggests that the potential beneficial effects of metformin seen in epidemiological studies may be limited to specific tumor types or be related to indirect effects/mechanisms not observed under acute laboratory conditions.

View Figures

View References

1	Broaddus E, Topham A and Singh AD: Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol. 93:21–23. 2009.
2	Rodriguez-Galindo CC, Wilson MWM, Haik BGB, et al: Treatment of metastatic retinoblastoma. Ophthalmology. 110:1237–1240. 2003. View Article : Google Scholar
3	Roarty JD, McLean IW and Zimmerman LE: Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology. 95:1583–1587. 1988. View Article : Google Scholar : PubMed/NCBI
4	Shaw RJ, Lamia KA, Vasquez D, et al: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 310:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
5	Marr BP, Hung C, Gobin YP, Dunkel IJ, Brodie SE and Abramson DH: Success of intra-arterial chemotherapy (chemo-surgery) for retinoblastoma: effect of orbitovascular anatomy. Arch Ophthalmol. 130:180–185. 2012. View Article : Google Scholar : PubMed/NCBI
6	Liu J, Li M, Song B, et al: Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol. 31:264–270. 2013. View Article : Google Scholar : PubMed/NCBI
7	Bianciotto C, Shields CL, Iturralde JC, Sarici A, Jabbour P and Shields JA: Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology. 119:843–849. 2012. View Article : Google Scholar : PubMed/NCBI
8	Muen WJ, Kingston JE, Robertson F, Brew S, Sagoo MS and Reddy MA: Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology. 119:611–616. 2012. View Article : Google Scholar : PubMed/NCBI
9	Miyano-Kurosaki N, Kurosaki K, Hayashi M, et al: 2-amino-phenoxazine-3-one suppresses the growth of mouse malignant melanoma B16 cells transplanted into C57BL/6Cr Slc mice. Biol Pharm Bull. 29:2197–2201. 2006. View Article : Google Scholar : PubMed/NCBI
10	Ghassemi F and Shields CL: Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 130:1268–1271. 2012. View Article : Google Scholar : PubMed/NCBI
11	Qu Z, Zhang Y, Liao M, Chen Y, Zhao J and Pan Y: In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res. 42:922–933. 2012. View Article : Google Scholar : PubMed/NCBI
12	Munier FL, Gaillard M-C, Balmer A, et al: Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 96:1078–1083. 2012. View Article : Google Scholar : PubMed/NCBI
13	Shields CLC, Honavar SGS, Shields JAJ, Demirci HH, Meadows ATA and Naduvilath TJT: Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol. 120:460–464. 2002. View Article : Google Scholar : PubMed/NCBI
14	Shields CL, Shelil A, Cater J, Meadows AT and Shields JA: Development of new retinoblastomas after 6 cycles of chemo-reduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol. 121:1571–1576. 2003. View Article : Google Scholar : PubMed/NCBI
15	Sussman DA, Escalona-Benz E, Benz MS, et al: Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. Arch Ophthalmol. 121:979–984. 2003. View Article : Google Scholar : PubMed/NCBI
16	Schefler AC, Cicciarelli N, Feuer W, Toledano S and Murray TG: Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Opthalmology. 114:162–169. 2007. View Article : Google Scholar
17	Shields CL: Forget-me-nots in the care of children with retinoblastoma. Semin Ophthalmol. 23:324–334. 2009. View Article : Google Scholar : PubMed/NCBI
18	Shields CL, Palamar M, Sharma P, et al: Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors. Arch Ophthalmol. 127:282–290. 2009. View Article : Google Scholar : PubMed/NCBI
19	Benz MS, Scott IU, Murray TG, Kramer D and Toledano S: Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol. 118:577–578. 2000.PubMed/NCBI
20	Nishimura S, Sato T, Ueda H and Ueda K: Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol. 19:4182–4183. 2001.PubMed/NCBI
21	Stumvoll M, Nurjhan N, Perriello G, Dailey G and Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 333:550–554. 1995. View Article : Google Scholar : PubMed/NCBI
22	Zhou G, Myers R, Li Y, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI
23	Hundal HS, Ramlal T, Reyes R, Leiter LA and Klip A: Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology. 131:1165–1173. 1992.
24	Sahra IB, Laurent K, Loubat A, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008. View Article : Google Scholar : PubMed/NCBI
25	Buzzai M, Jones RG, Amaravadi RK, et al: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67:6745–6752. 2007. View Article : Google Scholar
26	Cufi S, Corominas-Faja B, Vazquez-Martin A, et al: Metformin-induced preferential killing of breast cancer initiating CD44⁺CD24^−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2⁺ human breast cancer xenografts. Oncotarget. 3:395–398. 2012.PubMed/NCBI
27	Tomic T, Botton T, Cerezo M, et al: Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2:e1992011. View Article : Google Scholar : PubMed/NCBI
28	Kato K, Gong J, Iwama H, et al: The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560. 2012. View Article : Google Scholar : PubMed/NCBI
29	Martin MJ, Hayward R, Viros A and Marais R: Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2:344–355. 2012. View Article : Google Scholar : PubMed/NCBI
30	Phoenix KN, Vumbaca F and Claffey KP: Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 113:101–111. 2009. View Article : Google Scholar
31	Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
32	Zhuang Y and Miskimins WK: Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, down-regulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal. 3:182008. View Article : Google Scholar : PubMed/NCBI
33	Towler MC and Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 100:328–341. 2007. View Article : Google Scholar : PubMed/NCBI
34	Vijg J and Campisi J: Puzzles, promises and a cure for ageing. Nature. 454:1065–1071. 2008. View Article : Google Scholar : PubMed/NCBI
35	Moruno-Manchón JF, Pérez-Jiménez E and Knecht E: Glucose induces autophagy under starvation conditions by a p38 MAPK-dependent pathway. Biochem J. 449:497–506. 2013.PubMed/NCBI
36	Hardie DG: The LKB1-AMPK pathway-friend or foe in cancer? Cancer Cell. 23:131–142. 2013. View Article : Google Scholar : PubMed/NCBI
37	Doyle A, Zhang G, Abdel Fattah EA, Eissa NT and Li YP: Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J. 25:99–110. 2011. View Article : Google Scholar
38	Matsuzawa T, Kim B-H, Shenoy AR, Kamitani S, Miyake M and Macmicking JD: IFN-γ elicits macrophage autophagy via the p38 MAPK signaling pathway. J Immunol. 189:813–818. 2012.
39	Webber JL and Tooze SA: Coordinated regulation of autophagy by p38alpha MAPK through mAtg9 and p38IP. EMBO J. 29:27–40. 2010. View Article : Google Scholar : PubMed/NCBI
40	Thyagarajan A, Jedinak A, Nguyen H, et al: Triterpenes from Ganoderma Lucidum induce autophagy in colon cancer through the inhibition of p38 mitogen-activated kinase (p38 MAPK). Nutr Cancer. 62:630–640. 2010. View Article : Google Scholar : PubMed/NCBI
41	Osborne CK, Bolan G, Monaco ME and Lippman ME: Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci USA. 73:4536–4540. 1976. View Article : Google Scholar : PubMed/NCBI
42	Metformin insert 1–6, 2009. Distributed by: Bristol-Myers Squibb Company; Princeton, NJ 08543, USA: http://packagein-serts.bms.com/pi/pi_glucophage_xr.pdf.
43	Quinn BJ, Kitagawa H, Memmott RM, Gills JJ and Dennis PA: Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metabol. 24:469–480. 2013. View Article : Google Scholar : PubMed/NCBI
44	Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, et al: In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol. 668:373–382. 2011. View Article : Google Scholar : PubMed/NCBI
45	Hadad SM, Appleyard V and Thompson AM: Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 114:391–399. 2009.
46	Dool CJ, Mashhedi H, Zakikhani M, et al: IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Endocr Relat Cancer. 18:699–709. 2011. View Article : Google Scholar
47	Wilcock C and Bailey CJ: Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 24:49–57. 1994. View Article : Google Scholar : PubMed/NCBI
48	Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
49	Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A and Decensi A: Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev. 18:701–705. 2009. View Article : Google Scholar : PubMed/NCBI
50	Noto H, Goto A, Tsujimoto T and Noda M: Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 7:e334112012. View Article : Google Scholar : PubMed/NCBI
51	Becker C, Meier CR, Jick SS and Bodmer M: Case-control analysis on metformin and cancer of the esophagus. Cancer Causes Control. 24:1763–1770. 2013. View Article : Google Scholar : PubMed/NCBI
52	Becker C, Jick SS, Meier CR and Bodmer M: Metformin and the risk of endometrial cancer: a case-control analysis. Gynecol Oncol. 129:565–569. 2013. View Article : Google Scholar : PubMed/NCBI
53	Bodmer M, Becker C, Jick SS and Meier CR: Metformin does not alter the risk of lung cancer: a case-control analysis. Lung Cancer. 78:133–137. 2012. View Article : Google Scholar : PubMed/NCBI
54	Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 21:280–286. 2012. View Article : Google Scholar : PubMed/NCBI
55	Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE and Bergstralh EJ: Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol. 32:43.e1–7. 2013. View Article : Google Scholar : PubMed/NCBI
56	Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol. 107:620–626. 2012. View Article : Google Scholar : PubMed/NCBI
57	Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A and Sasidhar M: The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer. 12:4102012. View Article : Google Scholar : PubMed/NCBI
58	Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol. 123:200–204. 2011. View Article : Google Scholar : PubMed/NCBI
59	Bodmer M, Meier C, Krähenbühl S, Jick SS and Meier CR: Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 33:1304–1308. 2010. View Article : Google Scholar : PubMed/NCBI
60	Tomimoto A, Endo H, Sugiyama M, et al: Metformin suppresses intestinal polyp growth in Apc^Min/+ mice. Cancer Science. 99:2136–2141. 2008. View Article : Google Scholar : PubMed/NCBI
61	Theodoropoulou S, Kolovou PE, Morizane Y, et al: Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. FASEB J. 24:2620–2630. 2010. View Article : Google Scholar
62	Rattan R, Giri S, Singh AK and Singh I: 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem. 280:39582–39593. 2005. View Article : Google Scholar : PubMed/NCBI
63	Inoki KK, Zhu TT and Guan K-LK: TSC2 mediates cellular energy response to control cell growth and survival. Cell. 115:577–590. 2003. View Article : Google Scholar : PubMed/NCBI
64	Cheng SWY, Fryer LGD, Carling D and Shepherd PR: Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem. 279:15719–15722. 2004. View Article : Google Scholar : PubMed/NCBI
65	Sarbassov DD, Ali SM and Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol. 17:596–603. 2005. View Article : Google Scholar : PubMed/NCBI
66	Kondo Y, Kanzawa T, Sawaya R and Kondo S: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
67	Hawley SA, Gadalla AE, Olsen GS and Hardie DG: The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 51:2420–2425. 2002. View Article : Google Scholar : PubMed/NCBI
68	Kalender A, Selvaraj A, Kim SY, et al: Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11:390–401. 2010. View Article : Google Scholar : PubMed/NCBI
69	Liu B, Fan Z, Edgerton SM, et al: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
70	Li C, Liu VWS, Chan DW, Yao KM and Ngan HYS: LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells. Int J Gynecol Cancer. 22:15–22. 2012. View Article : Google Scholar : PubMed/NCBI
71	Capano M and Crompton M: Bax translocates to mitochondria of heart cells during simulated ischaemia: involvement of AMP-activated and p38 mitogen-activated protein kinases. Biochem J. 395:57–64. 2006. View Article : Google Scholar : PubMed/NCBI
72	Xi X, Han J and Zhang JZ: Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J Biol Chem. 276:41029–41034. 2001. View Article : Google Scholar : PubMed/NCBI
73	Würth R, Pattarozzi A, Gatti M, et al: Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle. 12:145–156. 2013.PubMed/NCBI
74	Bao B, Wang Z, Ali S, et al: Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prevent Res. 5:355–364. 2012. View Article : Google Scholar : PubMed/NCBI
75	Ben Sahra I, Regazzetti C, Robert G, et al: Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71:4366–4372. 2011.PubMed/NCBI
76	Soranna D, Scotti L, Zambon A, et al: Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist. 17:813–822. 2012. View Article : Google Scholar : PubMed/NCBI
77	Bost F, Sahra IB, Le Marchand-Brustel Y and Tanti JF: Metformin and cancer therapy. Curr Opin Oncol. 24:103–108. 2012. View Article : Google Scholar
78	Iliopoulos D, Hirsch HA and Struhl K: Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 71:3196–3201. 2011. View Article : Google Scholar : PubMed/NCBI
79	Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
80	Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA: Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 9:1057–1064. 2010. View Article : Google Scholar : PubMed/NCBI